MyFinsight
Home
Blog
About
Comprehensive loss
-$21,831K
(-41.93%↓ Y/Y)
Interest income
$1,761K
(-12.74%↓ Y/Y)
Non-cash royalty income
$972K
(1.14%↑ Y/Y)
Net loss
-$21,505K
(-39.38%↓ Y/Y)
Total other
comprehensive (loss) income
-$326K
(-779.17%↓ Y/Y)
Total other income
$2,733K
(-8.26%↓ Y/Y)
License And Service
$1,273K
Laboratory Research
Revenue
$356K
Loss from operations
-$24,238K
(-31.67%↓ Y/Y)
Unrealized (loss) gain on
marketable securities, net...
-$326K
(-779.17%↓ Y/Y)
Total revenue
$1,629K
(-8.33%↓ Y/Y)
Total costs and
expenses
$25,867K
(28.15%↑ Y/Y)
Research and development
$18,066K
(57.80%↑ Y/Y)
General and
administrative
$6,048K
(12.29%↑ Y/Y)
Licensing
$1,235K
(-7.49%↓ Y/Y)
Revaluation of contingent
consideration
$300K
(-80.00%↓ Y/Y)
Cost of revenue
$218K
(-57.67%↓ Y/Y)
Back
Back
Income Statement
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)
source: myfinsight.com